Related Experiment Video

Updated: May 11, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

[Methods for the correction of dysregulated erythropoesis in coronary heart disease]

N A Makarova

    Klinicheskaia Meditsina
    |May 11, 2013
    PubMed

    Insights

    This study reveals that inflammation, specifically TNF-alpha, inhibits erythropoietin (EPO) production in coronary heart disease (CHD) patients, contributing to anemia. Personalized correction strategies are crucial for managing erythropoiesis in CHD.

    Area of Science:

    • Cardiology
    • Hematology
    • Immunology

    Background:

    • Coronary heart disease (CHD) is frequently associated with anemia.
    • The mechanisms underlying dysregulated erythropoiesis in CHD patients are not fully understood.
    • Inflammation plays a significant role in various chronic diseases, including cardiovascular conditions.

    Purpose of the Study:

    • To investigate the pathogenetic mechanisms of erythropoiesis dysregulation in patients with coronary heart disease (CHD).
    • To identify the role of inflammation and iron metabolism in the development of anemia in CHD.
    • To inform the development of targeted therapeutic strategies for anemia in CHD.

    Main Methods:

    • Studied 72 patients with CHD (including myocardial infarction and chronic CHD) and 10 healthy controls.
    • Assessed peripheral blood characteristics, iron metabolism, and serum levels of inflammation markers (TNF-alpha) and erythropoietin (EPO).
    • Correlated clinical data with laboratory findings to elucidate pathogenetic pathways.

    Main Results:

    • Elevated TNF-alpha levels were observed in most CHD patients, inhibiting hepatic EPO synthesis.
    • Low hepcidin production was linked to increased EPO levels and reduced iron content in the blood.
    • Anemia in CHD patients appears to result from both inflammation and iron depletion.

    Conclusions:

    • Dysregulated erythropoiesis in CHD is multifactorial, involving inflammatory inhibition of EPO and iron deficiency.
    • Correction of anemia in CHD requires individualized approaches considering these interconnected mechanisms.
    • Understanding these pathways is essential for developing effective treatments for CHD-related anemia.

    More Related Videos

    Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells14:22

    Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

    Published on: July 16, 2011

    Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

    Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

    Published on: March 14, 2017

    Related Concept Videos

    Factors Affecting Erythropoiesis01:24

    Factors Affecting Erythropoiesis

    The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
    Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
    EPO then...
    Erythropoiesis01:14

    Erythropoiesis

    Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
    Erythropoiesis01:14

    Erythropoiesis

    Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.